The Generation Study (Novartis) [1]
This study is sponsored by the NIH, and the pharmaceutical company Novartis in partnership with the Banner Alzheimer’s Institute. The clinical research study CAPI015A2201J is being conducted to assess whether CAD106 is safe and has beneficial effects in people who may be at elevated risk for the onset of clinical symptoms of Alzheimer’s disease due to their age and genetic status (carrying two copies of a version of the APOE gene called APOE-ε4 allele). Additionally, this study will examine the effects of each of the two therapies CAD 106 and CNP520 given separately and targeting brain amyloid on cognition, global clinical status, and underlying pathology in participants at risk for the onset of clinical symptoms of AD.
Potential subjects must be cognitively intact individuals with 2 copies of the APOE-ε4 allele, age 60 to 75 years, inclusive, selected as they represent a population at particularly high risk of progression to MCI due to AD and/or dementia due to AD. The subject must score greater than a 24 on the Folstein (MMSE).
The clinical research study CAPI015A2201J is being conducted to assess whether CAD106 is safe and has beneficial effects in people who may be at elevated risk for the onset of clinical symptoms of Alzheimer’s disease due to their age and genetic status (carrying two copies of a version of the APOE gene called APOE-ε4 allele).
For more information, please contact Katie Brundage at (845) 398-6533 or katherine.brundage@nki.rfmh.org [2].